Efficacy of olocizumab in treatment of COVID-19 patients

Efficacy of olocizumab in treatment of COVID-19 patients

Background. Production of pro-inflammatory cytokines including interleukin 6 (IL-6) is activated in COVID-19. Using olokizumab which inhibits IL-6 production in treatment of COVID-19 is pathogenetically justified.The aim. To study in real clinical practice the efficacy and safety of using the IL-6in...

Full description

Saved in:

Bibliographic Details
Main Authors:	T. V. Goma, A. N. Kalyagin, O. V. Ryzhkova, N. S. Soloveva
Format:	Article
Language:	Russian
Published:	Scientific Сentre for Family Health and Human Reproduction Problems 2022-12-01
Series:	Acta Biomedica Scientifica
Subjects:	olokizumab artelegia coronavirus infection covid-19 pneumonia interleukin 6
Online Access:	https://www.actabiomedica.ru/jour/article/view/3828
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical case of olokizumab treatment in a patient with diffuse systemic sclerosis
by: E. S. Kuvardin, et al.
Published: (2022-11-01)

Olokizumab in patients with inflammatory phenotype of osteoarthritis, treatment experience
by: A. M. Lila, et al.
Published: (2024-06-01)

Efficacy and safety of olokizumab in the treatment of rheumatoid arthritis in real-world clinical practice in Kazakhstan
by: G. A. Togizbayev, et al.
Published: (2025-06-01)

Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study
by: T. A. Lisitsyna, et al.
Published: (2023-04-01)

CHARACTERISTICS OF OLOKIZUMAB PHARMACOKINETICS IN PATIENTS WITH NOVEL CORONAVIRUS INFECTION COVID-19
by: E. V. Tavlueva, et al.
Published: (2022-12-01)

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6)
by: E. L. Nasonov, et al.
Published: (2022-11-01)

Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01)

Risk of secondary bacterial infections during treatment with anti-inflammatory genetically engineered biological drugs in COVID-19 patients
by: V. I. Petrov, et al.
Published: (2025-03-01)

Experience of using the interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis in real-life clinical practice (based on data from Tyumen Regional Rheumatology Center)
by: I. M. Patrikeeva, et al.
Published: (2025-02-01)

Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. V. Fedorova, et al.
Published: (2024-06-01)

Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic
by: A. A. Akimova, et al.
Published: (2023-03-01)

Assessment of Clinical Efficacy of Dexamethasone in Patients with Moderate COVID-19
by: M. V. Tolochko, et al.
Published: (2022-02-01)

Role of interleukin-6 in COVID-19 pneumonia as marker of cytokine storm and predictor of course during hospitalization: Prospective, observational study in tertiary care setting in India
by: Shital Patil, et al.
Published: (2023-05-01)

Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy
by: P. A. Shesternya, et al.
Published: (2024-10-01)

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm
by: M. Yu. Frolov, et al.
Published: (2021-02-01)

Dynamics of clinical manifestations and cytokine concentrations in patients with rheumatoid arthritis on olokizumab therapy
by: N. A. Lapkina, et al.
Published: (2023-08-01)

Clinical features of patients with COVID19, hospitalized in a multi-somatic hospital
by: O. A. Markelovа, et al.
Published: (2021-10-01)

Tocilizumab: A potent immunomodulatory agent in the treatment of COVID-19 pneumonia
by: Sameer Bansal, et al.
Published: (2021-01-01)

Efficiency of Levilimab in patients with moderate and severe COVID-19
by: Yu. M. Gomon, et al.
Published: (2023-04-01)

The role of lung ultrasound in the COVID-19
by: D. O. Starostin, et al.
Published: (2020-09-01)

The Impact of Comorbidities on the Treatment Outcome in Patients With Severe Covid-19-Associated Pneumonia
by: N. A. Chulakova, et al.
Published: (2025-04-01)

Evaluation of Interleukin-6 and its Association with the Severity of Disease in COVID-19 Patients
by: Sudhir Bhandari, et al.
Published: (2020-07-01)

Management of patients with rheumatoid arthritis in real clinical practice: Switching from interleukin 6 receptor inhibitors to interleukin 6 inhibitor (olokizumab)
by: A. A. Baranov, et al.
Published: (2023-06-01)

COVID-19 Pneumonia Pneumomediastinum. Clinical Cases
by: N. А. Lesteva, et al.
Published: (2021-07-01)

Effect of interleukin 6 blockers on body composition, adipocytokines and insulin-like growth factor 1 in patients with rheumatoid arthritis
by: L. V. Kondratyeva, et al.
Published: (2025-07-01)

Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
by: V. T. Ivashkin, et al.
Published: (2023-12-01)

Pulmonary abscess as a complication of COVID-19 associated pneumonia: a clinical case
by: T. I. Kalenchits, et al.
Published: (2022-01-01)

Efficiency of il-6 inhibitor (olokizumab) in suppressing inflammation in patients with moderate COVID-19 pneumonia
by: N. G. Ganyukova, et al.
Published: (2020-12-01)

Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence
by: P. A. Shesternya, et al.
Published: (2025-04-01)

Gastrointestinal Bleeding in Patients With New Coronavirus Infection COVID-19
by: V. D. Anosov, et al.
Published: (2023-11-01)

The state of the cytokine system in patients with severe COVID-19
by: A. A. Grishaeva, et al.
Published: (2021-07-01)

Russian vaccines against COVID-19: their characteristics, efficacy and safety
by: A. E. Bilev, et al.
Published: (2023-01-01)

Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection
by: Juliane Lokau, et al.
Published: (2025-01-01)

Successful Treatment of Transplanted Kidney Patient with 100% Lung Damage Caused by COVID-19 Bilateral Pneumonia: a Clinical Case
by: R. R. Nuriakhmetov, et al.
Published: (2022-06-01)

IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6
by: E. L. Nasonov
Published: (2020-06-01)

The Cases of COVID-19 and Measles Co-Infection in Children
by: N. N. Zvereva, et al.
Published: (2022-01-01)

Correlation between oral health and severity of respiratory coronavirus infection COVID-19
by: A. V. Mitronin, et al.
Published: (2021-04-01)

Anal Swab in COVID-19 Patients
by: Sukamto Koesnoe, et al.
Published: (2022-09-01)

Early Changes in Clinical and Laboratory Parameters in Patients Died of COVID-19
by: K. S. Bakhtiyarova, et al.
Published: (2022-10-01)

Periodontal Disease Elevates IL-6 Levels During Initial Symptoms of COVID-19
by: Ruth Rodríguez-Montaño, et al.
Published: (2025-06-01)